| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| PLRZPolyrizon Ltd. | 16.19M | 15.54 | 31.08 | -5.21% | ||||
| TOVXTheriva Biologics, Inc. | 7.49M | 0.21 | -0.01 | -388.69% | 0.08 | |||
| CTXRCitius Pharmaceuticals, Inc. | 17.79M | 0.86 | -0.14 | -258.23% | -59.6% | 0.00 | ||
| ACXPAcurx Pharmaceuticals, Inc. | 6.32M | 2.69 | -0.15 | -0.25% | ||||
| ITRMIterum Therapeutics plc | 17.16M | 0.32 | -0.26 | -69.13% | ||||
| ANTXAN2 Therapeutics, Inc. | 34.25M | 1.25 | -0.73 | -56.29% | ||||
| MCRBSeres Therapeutics, Inc. | 137.33M | 15.18 | -0.80 | 15.37% | 12.34% | 6.65 | ||
| PYPDPolyPid Ltd. | 73.03M | 4.39 | -0.89 | -10.39% | 1.25 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 10.23M | 9.54M | 10.43M | 10.99M | 13.72M | 15.34M | 19.24M | 18.57M | 17.47M | 26.49M |
| Revenue Growth % | 0.35% | -0.07% | 0.09% | 0.05% | 0.25% | 0.12% | 0.25% | -0.04% | -0.06% | 0.52% |
| Cost of Goods Sold | 3.98M | 4.12M | 5.21M | 5.79M | 6.98M | 8.48M | 10.59M | 10.92M | 13.08M | 18.55M |
| COGS % of Revenue | 0.39% | 0.43% | 0.5% | 0.53% | 0.51% | 0.55% | 0.55% | 0.59% | 0.75% | 0.7% |
| Gross Profit | 6.25M | 5.42M | 5.22M | 5.19M | 6.74M | 6.86M | 8.66M | 7.65M | 4.4M | 7.94M |
| Gross Margin % | 0.61% | 0.57% | 0.5% | 0.47% | 0.49% | 0.45% | 0.45% | 0.41% | 0.25% | 0.3% |
| Gross Profit Growth % | 0.41% | -0.13% | -0.04% | -0.01% | 0.3% | 0.02% | 0.26% | -0.12% | -0.43% | 0.81% |
| Operating Expenses | 4.13M | 4.53M | 5.46M | 7.34M | 7.69M | 8.24M | 8.4M | 9.95M | 10.14M | 9.58M |
| OpEx % of Revenue | 0.4% | 0.47% | 0.52% | 0.67% | 0.56% | 0.54% | 0.44% | 0.54% | 0.58% | 0.36% |
| Selling, General & Admin | 2.89M | 3.29M | 3.42M | 3.82M | 4.01M | 3.89M | 4.23M | 5.45M | 5.22M | 5.68M |
| SG&A % of Revenue | 0.28% | 0.34% | 0.33% | 0.35% | 0.29% | 0.25% | 0.22% | 0.29% | 0.3% | 0.21% |
| Research & Development | 1.24M | 1.24M | 2.05M | 3.52M | 3.69M | 4.35M | 4.17M | 4.49M | 4.39M | 3.9M |
| R&D % of Revenue | 0.12% | 0.13% | 0.2% | 0.32% | 0.27% | 0.28% | 0.22% | 0.24% | 0.25% | 0.15% |
| Other Operating Expenses | 5.63K | -24.85K | 0 | 0 | 0 | 0 | 0 | 0 | 527K | 0 |
| Operating Income | 2.12M | 890.2K | -243K | -1.45M | -954K | -1.38M | 257.38K | -2.3M | -5.75M | -1.64M |
| Operating Margin % | 0.21% | 0.09% | -0.02% | -0.13% | -0.07% | -0.09% | 0.01% | -0.12% | -0.33% | -0.06% |
| Operating Income Growth % | 11.28% | -0.58% | -1.27% | -4.95% | 0.34% | -0.45% | 1.19% | -9.93% | -1.5% | 0.71% |
| EBITDA | 2.65M | 1.69M | 661.43K | 73.71K | 1.31M | 982.6K | 2.72M | 188.58K | -3.03M | 1.05M |
| EBITDA Margin % | 0.26% | 0.18% | 0.06% | 0.01% | 0.1% | 0.06% | 0.14% | 0.01% | -0.17% | 0.04% |
| EBITDA Growth % | 9.93% | -0.36% | -0.61% | -0.89% | 16.82% | -0.25% | 1.77% | -0.93% | -17.07% | 1.35% |
| D&A (Non-Cash Add-back) | 529.26K | 802.38K | 904.43K | 1.52M | 2.27M | 2.36M | 2.46M | 2.49M | 2.72M | 2.69M |
| EBIT | 2.15M | 890.2K | -219.91K | -1.43M | -835.63K | -714.35K | 237.39K | -2.14M | -5.22M | -1.62M |
| Net Interest Income | -64.41K | -107.03K | -201.66K | -413.48K | -311.04K | -385.25K | -295.55K | -195.44K | 0 | -491.02K |
| Interest Income | 19.17K | 54.66K | 16.91K | 14.3K | 118.28K | 27.44K | 18.81K | 153.1K | 0 | 77.7K |
| Interest Expense | 83.58K | 161.7K | 218.57K | 427.78K | 431.79K | 412.69K | 314.36K | 348.54K | 0 | 568.73K |
| Other Income/Expense | -58.77K | -131.88K | -195.63K | -413.48K | -313.59K | 347.88K | -326.51K | -186.81K | -21.89K | -506.41K |
| Pretax Income | 2.06M | 758.32K | -438K | -1.86M | -1.27M | -1.03M | -69.13K | -2.49M | -5.77M | -2.15M |
| Pretax Margin % | 0.2% | 0.08% | -0.04% | -0.17% | -0.09% | -0.07% | -0% | -0.13% | -0.33% | -0.08% |
| Income Tax | 850.31K | 249.87K | -270K | 462K | 28K | -10K | 9.16K | 8K | 4.63K | 10.06K |
| Effective Tax Rate % | 0.59% | 0.67% | 0.38% | 1.25% | 1.02% | 0.99% | 1.13% | 1% | 1% | 1% |
| Net Income | 1.21M | 508.45K | -168K | -2.32M | -1.3M | -1.02M | -78.29K | -2.49M | -5.77M | -2.16M |
| Net Margin % | 0.12% | 0.05% | -0.02% | -0.21% | -0.09% | -0.07% | -0% | -0.13% | -0.33% | -0.08% |
| Net Income Growth % | 8.26% | -0.58% | -1.33% | -12.82% | 0.44% | 0.21% | 0.92% | -30.86% | -1.32% | 0.63% |
| Net Income (Continuing) | 1.21M | 508.45K | -168.15K | -2.32M | -1.3M | -1.02M | -78.29K | -2.49M | -5.77M | -2.16M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.38 | 0.12 | -0.03 | -0.42 | -0.19 | -0.14 | -0.01 | -0.32 | -0.75 | -0.26 |
| EPS Growth % | 7.88% | -0.68% | -1.28% | -11.39% | 0.55% | 0.26% | 0.93% | -30.07% | -1.34% | 0.65% |
| EPS (Basic) | 0.40 | 0.12 | -0.03 | -0.42 | -0.19 | -0.14 | -0.01 | -0.32 | -0.75 | -0.26 |
| Diluted Shares Outstanding | 3.17M | 4.34M | 4.95M | 5.49M | 6.82M | 7.21M | 7.59M | 7.75M | 7.75M | 8.17M |
| Basic Shares Outstanding | 3.04M | 4.23M | 4.95M | 5.49M | 6.82M | 7.21M | 7.59M | 7.75M | 7.7M | 8.17M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 7.87M | 14.35M | 7.51M | 6.42M | 13.19M | 12.16M | 16.26M | 13.99M | 11.47M | 15.04M |
| Cash & Short-Term Investments | 6.04M | 10.62M | 3.8M | 2.52M | 8.77M | 7.95M | 10.19M | 5.79M | 978.74K | 3.76M |
| Cash Only | 1.57M | 5.15M | 3.8M | 2.52M | 6.29M | 7.95M | 10.19M | 5.79M | 978.74K | 3.76M |
| Short-Term Investments | 4.46M | 5.47M | 0 | 0 | 2.48M | 0 | -468 | 0 | 0 | 0 |
| Accounts Receivable | 745.06K | 1.14M | 1.49M | 1.43M | 1.68M | 1.86M | 2.72M | 1.8M | 2.19M | 3.81M |
| Days Sales Outstanding | 26.59 | 43.49 | 52.26 | 47.36 | 44.62 | 44.36 | 51.61 | 35.4 | 45.65 | 52.51 |
| Inventory | 870.21K | 2.13M | 2.05M | 2.33M | 2.52M | 2.09M | 3.09M | 6.04M | 7.81M | 7.11M |
| Days Inventory Outstanding | 79.85 | 188.28 | 143.6 | 146.94 | 131.63 | 90.08 | 106.53 | 201.86 | 218.07 | 139.94 |
| Other Current Assets | 37.3K | 333.11K | 0 | 0 | 800 | 800 | 0 | 0 | 39.73K | 0 |
| Total Non-Current Assets | 6.73M | 10.35M | 26.79M | 26.31M | 25.5M | 28.19M | 28.2M | 30.87M | 32.34M | 30.06M |
| Property, Plant & Equipment | 5.72M | 9.85M | 26.07M | 26.03M | 25.27M | 27.98M | 28M | 30.64M | 32.15M | 29.91M |
| Fixed Asset Turnover | 1.79x | 0.97x | 0.40x | 0.42x | 0.54x | 0.55x | 0.69x | 0.61x | 0.54x | 0.89x |
| Goodwill | 0 | 95.56K | 95.56K | 95.56K | 95.56K | 95.56K | 95.56K | 95.56K | 95.56K | 95.56K |
| Intangible Assets | 0 | 171.94K | 152.83K | 133.73K | 114.62K | 95.52K | 76.42K | 57.31K | 38.21K | 19.1K |
| Long-Term Investments | 487K | 0 | 0 | 40.21K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 49.71K | 34.26K | 920 | 53.16K | 26.88K | 26.17K | 26.11K | 76.63K | 57.66K | 33.37K |
| Total Assets | 14.6M | 24.7M | 34.3M | 32.73M | 38.69M | 40.35M | 44.47M | 44.86M | 43.81M | 45.1M |
| Asset Turnover | 0.70x | 0.39x | 0.30x | 0.34x | 0.35x | 0.38x | 0.43x | 0.41x | 0.40x | 0.59x |
| Asset Growth % | 0.32% | 0.69% | 0.39% | -0.05% | 0.18% | 0.04% | 0.1% | 0.01% | -0.02% | 0.03% |
| Total Current Liabilities | 817.59K | 2.06M | 2.06M | 2.57M | 2.5M | 2.21M | 2.53M | 3.07M | 4.2M | 4.41M |
| Accounts Payable | 199.1K | 1.51M | 580.46K | 603.74K | 572.18K | 602.35K | 745.04K | 790K | 887.73K | 943.64K |
| Days Payables Outstanding | 18.27 | 133.43 | 40.67 | 38.05 | 29.91 | 25.93 | 25.69 | 26.41 | 24.78 | 18.57 |
| Short-Term Debt | 130.78K | 133.27K | 316.63K | 1.34M | 1.27M | 760.34K | 812.21K | 1.04M | 1.43M | 1.5M |
| Deferred Revenue (Current) | 0 | 33.86K | 24.1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.51K | 0 | 0 | 0 | 175.11K | 0 | 0 | 0 | 306.78K | 0 |
| Current Ratio | 9.63x | 6.97x | 3.64x | 2.50x | 5.29x | 5.50x | 6.42x | 4.56x | 2.73x | 3.41x |
| Quick Ratio | 8.57x | 5.94x | 2.64x | 1.59x | 4.28x | 4.55x | 5.20x | 2.59x | 0.87x | 1.80x |
| Cash Conversion Cycle | 88.17 | 98.34 | 155.2 | 156.25 | 146.34 | 108.5 | 132.45 | 210.85 | 238.94 | 173.88 |
| Total Non-Current Liabilities | 3.17M | 2.92M | 8.64M | 8.42M | 7.21M | 9.87M | 9.35M | 11.41M | 14.62M | 13.17M |
| Long-Term Debt | 3.05M | 2.88M | 8.64M | 8.42M | 7.15M | 8.74M | 8.33M | 9.19M | 10.54M | 9.04M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 1.14M | 1.03M | 2.22M | 4.08M | 4.13M |
| Deferred Tax Liabilities | 19.59M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 78.53K | 37.35K | 996 | 0 | 58.52K | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 3.99M | 4.98M | 10.7M | 10.99M | 9.7M | 12.08M | 11.89M | 14.48M | 18.82M | 17.58M |
| Total Debt | 3.23M | 3.01M | 8.96M | 9.77M | 8.42M | 10.73M | 10.27M | 12.48M | 16.69M | 15.1M |
| Net Debt | 1.65M | -2.14M | 5.16M | 7.24M | 2.13M | 2.79M | 89.03K | 6.69M | 15.71M | 11.34M |
| Debt / Equity | 0.30x | 0.15x | 0.38x | 0.45x | 0.29x | 0.38x | 0.32x | 0.41x | 0.67x | 0.55x |
| Debt / EBITDA | 1.22x | 1.78x | 13.54x | 132.49x | 6.41x | 10.92x | 3.78x | 66.18x | - | 14.42x |
| Net Debt / EBITDA | 0.62x | -1.26x | 7.80x | 98.29x | 1.62x | 2.84x | 0.03x | 35.46x | - | 10.83x |
| Interest Coverage | 25.39x | 5.51x | -1.11x | -3.38x | -2.21x | -3.34x | 0.82x | -6.60x | - | -2.88x |
| Total Equity | 10.61M | 19.72M | 23.59M | 21.74M | 28.99M | 28.27M | 32.58M | 30.38M | 24.99M | 27.52M |
| Equity Growth % | 0.15% | 0.86% | 0.2% | -0.08% | 0.33% | -0.03% | 0.15% | -0.07% | -0.18% | 0.1% |
| Book Value per Share | 3.35 | 4.55 | 4.77 | 3.96 | 4.25 | 3.92 | 4.29 | 3.92 | 3.23 | 3.37 |
| Total Shareholders' Equity | 10.61M | 19.72M | 23.59M | 21.74M | 28.99M | 28.27M | 32.58M | 30.38M | 24.99M | 27.52M |
| Common Stock | 326.12K | 504.48K | 566.26K | 566.26K | 729.9K | 729.9K | 781.42K | 781.42K | 781.42K | 904.24K |
| Retained Earnings | 638.67K | 1.15M | 978.97K | -1.34M | -2.64M | -3.66M | -3.74M | -6.23M | -12.01M | -14.16M |
| Treasury Stock | -450.9K | -431.94K | -407.88K | -204.95K | -188.34K | -175.39K | -158.17K | -147.23K | -138.48K | -138.48K |
| Accumulated OCI | -50.26K | -23.9K | -638 | 30.16K | -43.9K | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 2.9M | -323.9K | 1.18M | -373.4K | 233.51K | 1.32M | 954.17K | -1.54M | -4.67M | 357.9K |
| Operating CF Margin % | 0.28% | -0.03% | 0.11% | -0.03% | 0.02% | 0.09% | 0.05% | -0.08% | -0.27% | 0.01% |
| Operating CF Growth % | 8.59% | -1.11% | 4.63% | -1.32% | 1.63% | 4.63% | -0.27% | -2.62% | -2.03% | 1.08% |
| Net Income | 1.21M | 508.45K | -168.15K | -2.32M | -1.3M | -1.02M | -78.29K | -2.49M | -5.77M | -2.16M |
| Depreciation & Amortization | 529.26K | 802.38K | 904.43K | 1.52M | 2.27M | 2.35M | 2.46M | 2.49M | 2.72M | 2.69M |
| Stock-Based Compensation | 23.22K | 67.4K | 199.78K | 344.02K | 313.14K | 253.13K | 144.31K | 266.24K | 368.87K | 326K |
| Deferred Taxes | 821.47K | 236.29K | -284.81K | 462.31K | 24.68K | -14.63K | 30.96K | 0 | 0 | 0 |
| Other Non-Cash Items | -3.98K | 37.51K | -8.36K | -681.44K | 19.45K | -780.35K | 18.56K | 28.8K | 260.82K | -91.76K |
| Working Capital Changes | 317.03K | -1.98M | 532.92K | 302.66K | -1.1M | 532.26K | -1.62M | -1.83M | -2.27M | -406.52K |
| Change in Receivables | 251.19K | -277.52K | -330.31K | 411.72K | -704.87K | -159.64K | -897.43K | 935.63K | 0 | -1.59M |
| Change in Inventory | 75.55K | -1.14M | 77.17K | -281.94K | -186.59K | 425.74K | -997.46K | -2.95M | 0 | 699.22K |
| Change in Payables | 60.36M | -182.51M | 448.64M | 196.98K | -190.21K | 299.88M | 245.76M | 342 | 157K | 362.61K |
| Cash from Investing | -4.62M | -4.42M | -12.27M | -1.79M | -3.4M | -2.57M | -1.6M | -3.96M | -1.89M | -461.23K |
| Capital Expenditures | -2.72M | -3.59M | -17.76M | -2.03M | -1.39M | -4.07M | -2.61M | -3.98M | -1.89M | -465.73K |
| CapEx % of Revenue | 0.27% | 0.38% | 1.7% | 0.18% | 0.1% | 0.27% | 0.14% | 0.21% | 0.11% | 0.02% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 66.22K | 30.94K | 45K | 250K | 450K | 45.6K | 15.29K | 11K | 2.47K | 4.5K |
| Cash from Financing | 2.44M | 8.32M | 9.75M | 889.62K | 6.94M | 1.91M | 3.88M | 1.11M | 1.75M | 2.88M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 111.79K | -14.76K | 3.75M | 94.28K | 8.3M | -53.13K | 13.96K | 11.36K | -62.77K | -5.04K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | 181.05K | -3.91M | -16.58M | -2.4M | -1.16M | -2.76M | -1.65M | -5.52M | -6.57M | -107.82K |
| FCF Margin % | 0.02% | -0.41% | -1.59% | -0.22% | -0.08% | -0.18% | -0.09% | -0.3% | -0.38% | -0% |
| FCF Growth % | 1.15% | -22.6% | -3.24% | 0.86% | 0.52% | -1.38% | 0.4% | -2.34% | -0.19% | 0.98% |
| FCF per Share | 0.06 | -0.90 | -3.35 | -0.44 | -0.17 | -0.38 | -0.22 | -0.71 | -0.85 | -0.01 |
| FCF Conversion (FCF/Net Income) | 2.39x | -0.64x | -7.00x | 0.16x | -0.18x | -1.29x | -12.19x | 0.62x | 0.81x | -0.17x |
| Interest Paid | 77.16K | 153.09K | 186.54K | 403.54K | 420.96K | 481.41K | 308.68K | 338.52K | 0 | 528.91K |
| Taxes Paid | 3.13K | 123.58K | 6.07K | 4.22K | 3.57K | 4.58K | 5.11K | 4.92K | 0 | 7.29K |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 12.21% | 3.35% | -0.78% | -10.24% | -5.11% | -3.57% | -0.26% | -7.92% | -20.86% | -8.21% |
| Return on Invested Capital (ROIC) | 14.76% | 4.47% | -0.79% | -3.76% | -2.38% | -3.33% | 0.61% | -4.95% | -11.09% | -3.09% |
| Gross Margin | 61.11% | 56.8% | 50.05% | 47.28% | 49.11% | 44.73% | 44.98% | 41.19% | 25.16% | 29.97% |
| Net Margin | 11.86% | 5.33% | -1.61% | -21.14% | -9.44% | -6.66% | -0.41% | -13.43% | -33.05% | -8.14% |
| Debt / Equity | 0.30x | 0.15x | 0.38x | 0.45x | 0.29x | 0.38x | 0.32x | 0.41x | 0.67x | 0.55x |
| Interest Coverage | 25.39x | 5.51x | -1.11x | -3.38x | -2.21x | -3.34x | 0.82x | -6.60x | - | -2.88x |
| FCF Conversion | 2.39x | -0.64x | -7.00x | 0.16x | -0.18x | -1.29x | -12.19x | 0.62x | 0.81x | -0.17x |
| Revenue Growth | 34.64% | -6.69% | 9.29% | 5.32% | 24.91% | 11.8% | 25.43% | -3.51% | -5.9% | 51.63% |
| 2021 | 2023 | 2024 | |
|---|---|---|---|
| FirstDefenseProductLineMember | 18.93M | - | - |
| FirstDefenseProductLineMember Growth | - | - | - |
| OtherAnimalHealthMember | 309.88K | - | - |
| OtherAnimalHealthMember Growth | - | - | - |
| 2021 | 2023 | 2024 | |
|---|---|---|---|
| UNITED STATES | 16.62M | 15.95M | 22.89M |
| UNITED STATES Growth | - | -4.04% | 43.54% |
| OtherStatesMember | 2.62M | - | - |
| OtherStatesMember Growth | - | - | - |
ImmuCell Corporation (ICCC) reported $28.3M in revenue for fiscal year 2024. This represents a 453% increase from $5.1M in 2011.
ImmuCell Corporation (ICCC) grew revenue by 51.6% over the past year. This is strong growth.
Yes, ImmuCell Corporation (ICCC) is profitable, generating $1.8M in net income for fiscal year 2024 (-8.1% net margin).
ImmuCell Corporation (ICCC) has a return on equity (ROE) of -8.2%. Negative ROE indicates the company is unprofitable.
ImmuCell Corporation (ICCC) generated $1.8M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.